An interventional study of Biopsy and fluid samples in Gastrointestinal Diseases, sponsored by Baylor Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Baylor Research Institute · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Gastrointestinal Diseases with a site in United States — 32 open to participants now, 42 under way, 5 of them phase 3. Gastrointestinal Diseases · United States.
Among the 200 studies in Gastrointestinal Diseases with a site in United States, this one is the 87th largest by planned enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2020, is one of 63 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 145th registered.
549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.
Browse Gastrointestinal Diseases studies →32 of the 200 studies in Gastrointestinal Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 6 mo+ · Healthy volunteers
Northwestern University · Sites in United States
Ages 18+
Baylor College of Medicine · Sites in United States
Ages 7–12
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
Zealand Pharma · Sites in United States, Austria, Belgium and 11 more countries
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 39 · Phase 3 27 · Phase 4 7
First in 1995; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.
Median enrollment 90 across the 141 interventional studies, 250 across the 57 observational. Of the 138 that completed or were terminated, 52 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 200 have an industry lead sponsor. The 10 most frequent:
Baylor Research Institute is the lead sponsor of 224 studies on the registry; 48 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.
Baylor Research Institute has 1 study filed under Gastrointestinal Diseases — fewer than ten, so there is no comparison to draw.
15 of the studies in Gastrointestinal Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776277Phase 3Cook MyoSiteIltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury | 2026-12 |
| NCT05501028Massachusetts General HospitalNLP to Aid in the Evaluation and Diagnosis of FGIDs | 2026-12 |
| NCT05212129Medical College of WisconsinAuricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome | 2026-12-31 |
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT07351071Medtronic - MITGPost-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | 2027-04-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 200 studies in Gastrointestinal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aims
For this study, investigators will compare the microbial composition of the infected fluid from the leak to that of a tissue sample taken from the participant. This will allow investigators to compare the composition and virulence of the microbiome both within and between participants. These comparisons will help further the understanding of the pathogenesis of these leaks, as well as identify which participants may be most at risk of developing postoperative leaks. The combination of this information has the potential to contribute to the development of preventative measures and improve patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Samples of microbial fluid and host biopsy taken
Other: Biopsy and fluid samples
Biopsy and fluid samples taken during other medically necessary procedure
Microbial composition of samples
change in virulence factors, microbial response to treatment modalities
Time frame: During the surgery
Time of healing of leaks
Time from index intervention to confirmed leaked closure as determined by imaging or endoscopic evaluation.
Time frame: From index intervention until documented leak resolution ( up to 24 weeks)
Proportion of patients achieving leak closure without need for additional surgical intervention
Successful endoscopic management will be defined as complete leak resolution without requirement for subsequent operative surgical repair. This will be measured as a percentage of participants.
Time frame: Up to 24 weeks post-surgery
Incidence of postoperative complications
Complications occurring within 30 days of surgery will be recorded. Percentage of participants with complications will be recorded.
Time frame: Within 30 days post-surgery
Patient demographics
age, sex, race, ethnicity
Time frame: Baseline or anytime before surgery
Patient risk of postoperative complications
Calculated by ACS risk calculator
Time frame: Post surgery until the time leak is healed ( up to 24 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2020 (actual). Primary completion is estimated for Jul 2027, 82 months after the start.
Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 82 months is above that.
Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.